Metrion Biosciences

We show concentration response curves of reference compounds against TREK-1 activity from the Qube 384 assay. (A, B) Concentration-response curves of different inhibitors (A) and activators (B). Data were fitted using a variable Hill slope, four-parameter curve. Curves were restraint between 0 – 100 % (inhibitors) or from 0 % (activators). (C) IC50 values derived from the concentration-response fits in A and B and corresponding IC50 values reported in the literature. Data displayed as Mean ± SEM. Read more in our 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗡𝗼𝘁𝗲 '𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗮𝗻𝗱 𝘃𝗮𝗹𝗶𝗱𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗮 𝗱𝘂𝗮𝗹 𝗺𝗼𝗱𝗮𝗹𝗶𝘁𝘆 𝗧𝗥𝗘𝗞-𝟭 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝗮𝘀𝘀𝗮𝘆 𝗼𝗻 𝘁𝗵𝗲 𝗮𝘂𝘁𝗼𝗺𝗮𝘁𝗲𝗱 𝗽𝗮𝘁𝗰𝗵 𝗰𝗹𝗮𝗺𝗽 𝗤𝘂𝗯𝗲 𝟯𝟴𝟰 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺': https://hubs.la/Q02Wj9fR0 #drugdiscovery #screening #ionchannels

Cost is a critical consideration for companies outsourcing their GLP hERG testing. 💲 Metrion offers a highly competitive pricing structure, making it possible for organizations of all sizes to access premium GLP hERG testing services without straining their budgets. 💲 Quality of data not sacrificed. 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐨𝐮𝐫 𝐡𝐢𝐠𝐡-𝐪𝐮𝐚𝐥𝐢𝐭𝐲, 𝐜𝐨𝐬𝐭-𝐞𝐟𝐟𝐞𝐜𝐭𝐢𝐯𝐞 𝐚𝐧𝐝 𝐫𝐚𝐩𝐢𝐝-𝐭𝐮𝐫𝐧𝐚𝐫𝐨𝐮𝐧𝐝, 𝐆𝐋𝐏 𝐭𝐞𝐬𝐭𝐢𝐧𝐠 𝐚𝐠𝐚𝐢𝐧𝐬𝐭 𝐡𝐄𝐑𝐆: https://hubs.la/Q02VscjZ0 #drugdiscovery #glp #glphERG #hERG

Tony Rush and Nicola Secomandi look forward to attending the Axion BioSystems UK Maestro MEA User Meeting tomorrow, where they will meet scientists across academia and industry in the field of neuroscience, to share knowledge and foster collaborations, as well as hear about the latest advancements with the Maestro platform. https://hubs.la/Q02VZWG20 #neuroscience #cns #drugdiscovery

We show Qube 384 screening of TREK-1 activity using reference compounds. (A, B) Representative TREK-1 current traces in the presence and absence of Amitriptyline (A, 100 μM) and BL-1249 (B, 10 μM). (C) Current-time plot overlay of different CHO-TREK-1 cells exposed to various reference inhibitors, activators or vehicle. A final BL-1249 application was used to verify current expression but has been truncated for clarity. Recordings performed in multi-hole acquisition using a Qube 384 platform at 25 oC. Read more in our 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗡𝗼𝘁𝗲 '𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗮𝗻𝗱 𝘃𝗮𝗹𝗶𝗱𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗮 𝗱𝘂𝗮𝗹 𝗺𝗼𝗱𝗮𝗹𝗶𝘁𝘆 𝗧𝗥𝗘𝗞-𝟭 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝗮𝘀𝘀𝗮𝘆 𝗼𝗻 𝘁𝗵𝗲 𝗮𝘂𝘁𝗼𝗺𝗮𝘁𝗲𝗱 𝗽𝗮𝘁𝗰𝗵 𝗰𝗹𝗮𝗺𝗽 𝗤𝘂𝗯𝗲 𝟯𝟴𝟰 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺': https://hubs.la/Q02KWCGN0 #drugdiscovery #screening #ionchannels

Retain the anatomical architecture of brain tissue and the synaptic circuitry within for a more holistic understanding of the effects of pharmacological compounds on the entire tissue, which may directly or indirectly affect neuronal ion channel function and excitatory activity. https://hubs.la/Q02TNJMV0 #drugdiscovery #CRO #CNS #Neuroscience #ionchannels

One of the key strengths of Metrion’s GLP hERG testing service is the rapid turnaround time. In the fast-paced world of drug discovery, delays in safety testing can slow down the entire discovery process, potentially leading to increased costs and lost opportunities. We understand this urgency and have streamlined processes to deliver GLP hERG testing results in a timeframe that supports the accelerated pace of modern drug discovery. 🕜 Speed does not come at the expense of quality. 🕜 Every assay is meticulously conducted. 🕜 Data is rigorously analysed to ensure it meets the highest standards. 𝐌𝐞𝐭𝐫𝐢𝐨𝐧 𝐩𝐫𝐨𝐯𝐢𝐝𝐞𝐬 𝐡𝐢𝐠𝐡-𝐪𝐮𝐚𝐥𝐢𝐭𝐲, 𝐜𝐨𝐬𝐭-𝐞𝐟𝐟𝐞𝐜𝐭𝐢𝐯𝐞 𝐚𝐧𝐝 𝐫𝐚𝐩𝐢𝐝-𝐭𝐮𝐫𝐧𝐚𝐫𝐨𝐮𝐧𝐝, 𝐆𝐋𝐏 𝐭𝐞𝐬𝐭𝐢𝐧𝐠 𝐚𝐠𝐚𝐢𝐧𝐬𝐭 𝐡𝐄𝐑𝐆: https://hubs.la/Q02MlVbd0 #drugdiscovery #glp #glphERG #hERG

Today is World Values Day, and this year's theme, "Bringing Values to Life", truly resonates with us at Metrion. Our values aren't just words - they guide us in everything we do. Each day, our team lives out these principles, shaping the culture we’re proud of. By staying true to our values, we create an environment where collaboration, innovation, and excellence thrive. We will continue to bring our values to life - today and every day! https://hubs.la/Q02TN5-c0 #WorldValuesDay #CompanyValues #CultureMatters

𝐒𝐞𝐜𝐨𝐧𝐝 𝐚𝐰𝐚𝐫𝐝 𝐫𝐞𝐜𝐞𝐢𝐯𝐞𝐝 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝐒𝐚𝐟𝐞𝐭𝐲 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐨𝐥𝐨𝐠𝐲 𝐒𝐨𝐜𝐢𝐞𝐭𝐲: '𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐏𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐀𝐰𝐚𝐫𝐝' Last year Robert Kirby worked alongside authors from Amgen to publish 'Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in Human Ether-a-Go-Go-Related Gene Assays' (Nucleic Acid Therapeutics). We're delighted this work has received the '2024 Technology Innovation Publication Award' from the Safety Pharmacology Society and send our congratulations to all authors. https://hubs.la/Q02TnwN50 Read about this work: https://hubs.la/Q02TnchH0 #drugdiscovery #hERG #GLPhERG

𝐒𝐞𝐜𝐨𝐧𝐝𝐚𝐫𝐲 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐨𝐥𝐨𝐠𝐲 𝐩𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐫𝐞𝐜𝐨𝐠𝐧𝐢𝐬𝐞𝐝 𝐚𝐬 ‘𝐌𝐨𝐬𝐭 𝐈𝐦𝐩𝐚𝐜𝐭𝐟𝐮𝐥 𝐏𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐭𝐡𝐞 𝐘𝐞𝐚𝐫’ 𝐛𝐲 𝐭𝐡𝐞 𝐒𝐚𝐟𝐞𝐭𝐲 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐨𝐥𝐨𝐠𝐲 𝐒𝐨𝐜𝐢𝐞𝐭𝐲 Prior to joining Metrion Steve Jenkinson co-chaired the Secondary Pharmacology Working Group under the auspice of the IQ DruSafe Consortium. The team conducted an extensive survey to highlight similarities and differences in screening strategies and target panels across the pharmaceutical industry and as a result identified a number of opportunities for further optimisation within the secondary pharmacology assessment of novel compounds (published in Nature Reviews in Drug Discovery). Metrion would like to congratulate IQ Consortium and all authors on this work receiving the 'Most Impactful Safety Pharmacology Publication of the Year' by the Safety Pharmacology Society. https://hubs.la/Q02Tnbt90 Read more about this work: https://hubs.la/Q02Tn9wf0 #drugdiscovery #secondarypharmacology #hERG

Our panel of models allow for more accurate prediction of human responses, reduce the risk of late-stage failures and provide a thorough understanding of drug mechanisms. ✔️ Ion channel expressing cell lines for central and peripheral nervous system targets ✔️Primary neuronal cultures, including dissociated cortical, trigeminal or dorsal root ganglion (DRG) neurons from rodents (Figure 1) ✔️CNS drug discovery to understand the effects of test compounds on brain slice tissue ✔️Human iPSC-derived neurons https://hubs.la/Q02PYN5h0 #drugdiscovery #CRO #CNS #Neuroscience #ionchannels